LYTACs, or Lysosome Targeting Chimeras, are cutting-edge bifunctional molecules designed to target and degrade specific proteins outside cells by directing them to the lysosome, a cellular organelle responsible for degradation. By harnessing the cell’s natural lysosomal degradation pathway, LYTACs can target and eliminate disease-associated proteins present outside of cells, including those involved in inflammation, cancer, and neurodegenerative disorders. This innovative approach offers a promising avenue for therapeutic development, with the potential to address a wide range of diseases that were previously challenging to target using traditional drug modalities. As research in LYTAC technology continues to advance, it holds significant promise for transforming the landscape of medicine and improving patient outcomes.
LYTACs consist of three components:
- Lysosomal receptor ligand
- Target protein binder
- Linker connecting both entities
Lifesensors offers unique and physiologically relevant target ubiquitination and degradation assays that allows rapid characterization of LYTACs for their specificity and potency.
LifeSensors helps you study LYTACs to make breakthrough discoveries and pave the way to novel therapeutics.